NCT07601867 Effect of Dapagliflozin on Right Ventricular-Pulmonary Artery Coupling After Off-Pump Coronary Atery Bypass Grafting
| NCT ID | NCT07601867 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Pyatigorsk City Clinical Hospital Number 1 |
| Condition | Heart Failure |
| Study Type | OBSERVATIONAL |
| Enrollment | 72 participants |
| Start Date | 2026-07-01 |
| Primary Completion | 2028-05-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 72 participants in total. It began in 2026-07-01 with a primary completion date of 2028-05-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This prospective, single-center observational study evaluates the effect of dapagliflozin 10 mg/day on right ventricular-pulmonary artery coupling measured by the TAPSE/PASP ratio in 72 patients with left ventricular ejection fraction \<50% after off-pump coronary artery bypass grafting (OPCAB). The primary outcome is the change in TAPSE/PASP ratio from 1 month after surgery (before dapagliflozin) to 7 months after surgery (after 6 months of dapagliflozin therapy).
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years * Elective isolated off-pump coronary artery bypass grafting (OPCAB) * Left ventricular ejection fraction (LVEF) \< 50% documented on pre-operative echocardiography * Written informed consent Exclusion Criteria: * Concomitant valve surgery * Emergency or urgent CABG * Conversion to on-pump during surgery * Perioperative myocardial infarction (as defined by the Fourth Universal Definition of MI) * Cardiogenic shock * More than moderate valvular heart disease * Persistent atrial fibrillation or atrial flutter at the time of echocardiographic examination) * Previous CABG or any prior cardiac surgery * Severe chronic kidney disease (eGFR \< 25 mL/min/1.73 m²) * Contraindication to SGLT2 inhibitors * Inability to obtain adequate echocardiographic windows * Pregnancy or breastfeeding
Contact & Investigator
Samson S. Badalyan, MD, PhD
PRINCIPAL INVESTIGATOR
Pyatigorsk City Clinical Hospital Number 1
Frequently Asked Questions
Who can join the NCT07601867 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Heart Failure. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07601867 currently recruiting?
Yes, NCT07601867 is actively recruiting participants. Contact the research team at sambadalyan@mail.ru for enrollment information.
Where is the NCT07601867 trial being conducted?
This trial is being conducted at Pyatigorsk, Russia.
Who is sponsoring the NCT07601867 clinical trial?
NCT07601867 is sponsored by Pyatigorsk City Clinical Hospital Number 1. The principal investigator is Samson S. Badalyan, MD, PhD at Pyatigorsk City Clinical Hospital Number 1. The trial plans to enroll 72 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.